The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
As automation becomes a critical lever for reducing production costs in the biotech sector, Cellares has expanded its Series D financing round to a total of $327 million. This expansion follows a fresh $50 million investment from Prime Radiant Partners aimed at accelerating the company's global automated manufacturing network. The capital is specifically earmarked for the expansion of 'Smart Factories,' including a new GMP-ready facility in the Netherlands slated for completion by 2027.
The funding round underscores strong conviction from tier-1 institutional investors, with the company backed by major names including BlackRock, ARK Invest, and T. Rowe Price. Compared to historical funding trends in biotech infrastructure, this capital injection positions Cellares to address the manufacturing bottlenecks that currently limit patient access to cell therapies. Per market data, investor interest in pharmaceutical automation remains robust as firms seek to scale complex therapeutic productions.
Sign in to access this content
Sign InRegarding sector-related performance, the instrument 0QZZ.L stood at $1027.54 (close June 12, 2026), having traded within a range of $994.86 to $1043.00. Looking ahead, market participants will monitor the U.S. CPI data release on June 10, 2026, for its potential impact on venture capital sentiment. The construction progress of the Netherlands facility remains the primary operational catalyst to watch for future valuation adjustments.